Because cancer checkpoint immunotherapies induce T cell proliferation, they are predicted to expand the population of KLRG1+ cells, resulting in a homeostatic checkpoint brake on efficacy contributing to adaptive resistance. This evidence concerns the gene KLRG1 and cancer.